NASDAQ:CLBS Caladrius Biosciences (CLBS) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free CLBS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.43▼$8.3852-Week Range N/AVolume466,373 shsAverage Volume522,308 shsMarket Capitalization$26.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Caladrius Biosciences alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Caladrius Biosciences Stock (NASDAQ:CLBS)Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CLBS Stock News HeadlinesDecember 1, 2022 | finance.yahoo.comHARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONSeptember 16, 2022 | finanznachrichten.deCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. September 15, 2022 | finanznachrichten.deCaladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 15, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 14, 2022 | seekingalpha.comCLBS Caladrius Biosciences, Inc.September 14, 2022 | finance.yahoo.comCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 8, 2022 | msn.comHow to get the Protea Caladrius collection in Warframe: VeilbreakerApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. September 8, 2022 | finance.yahoo.comCaladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022August 10, 2022 | finance.yahoo.comCaladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic CancerAugust 5, 2022 | seekingalpha.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comCaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 4, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANTAugust 3, 2022 | msn.comEarnings Outlook For Caladrius BiosciencesAugust 2, 2022 | finance.yahoo.comCaladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseJuly 28, 2022 | finance.yahoo.comCaladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeJuly 6, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and HepatologyJune 9, 2022 | finance.yahoo.comCaladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials GroupJune 8, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the BIO International Convention 2022May 26, 2022 | finance.yahoo.comCaladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual MeetingMay 24, 2022 | finance.yahoo.comCaladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease StudyMay 23, 2022 | finance.yahoo.comCaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionMay 19, 2022 | finance.yahoo.comCaladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney DiseaseMay 18, 2022 | finance.yahoo.comCaladrius Biosciences to Present at the H.C. Wainwright Global Investment ConferenceMay 6, 2022 | benzinga.comCALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBSMay 6, 2022 | seekingalpha.comCaladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call TranscriptSee More Headlines Receive CLBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNASDAQ:CLBS CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees27Year Founded2006Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.24% Return on Assets-26.08% Debt Debt-to-Equity RatioN/A Current Ratio22.33 Quick Ratio22.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares60,583,000Free Float59,250,000Market Cap$26.05 million OptionableOptionable Beta0.91 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. David J. Mazzo B.A. (Hons) (Age 65)B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director Comp: $957.69kDr. Kristen K. Buck M.D. (Age 48)Exec. VP of R&D and Chief Medical Officer Comp: $825kMr. James NiscoVP of Fin. & TreasuryMr. Gregory S. BerkinChief Information OfficerMr. John D. MendittoVP of Investor Relations & Corp. CommunicationsEric PowersDirector of Communications and MarketingMs. Gail Holler (Age 63)VP of HR Dr. Ian Zhang Ph.D. (Age 57)MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc Dr. William K. Sietsema Ph.D. (Age 66)VP of Global Regulatory Affairs More ExecutivesKey CompetitorsAcurx PharmaceuticalsNASDAQ:ACXPAileron TherapeuticsNASDAQ:ALRNEyenoviaNASDAQ:EYENMovanoNASDAQ:MOVESol-Gel TechnologiesNASDAQ:SLGLView All Competitors CLBS Stock Analysis - Frequently Asked Questions How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences, Inc. (NASDAQ:CLBS) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.95) by $0.15. During the same period in the prior year, the business earned ($4.35) earnings per share. When did Caladrius Biosciences' stock split? Shares of Caladrius Biosciences reverse split before market open on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO? 1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend. What other stocks do shareholders of Caladrius Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Karyopharm Therapeutics (KPTI), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), AcelRx Pharmaceuticals (ACRX) and CTI BioPharma (CTIC). This page (NASDAQ:CLBS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
